Importantly, ReACp53, a peptide designed to inhibit mutant p53 aggregation, has shown promising results in reducing the aggressiveness of mutant p53 tumors by restoring the tumor suppressor activity of p53, reactivating mitochondrial apoptotic pathways, and enhancing the susceptibility of cancer cells to existing treatments. Here, TP53 is linked to cancer.